## Peter J Mullen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10788018/publications.pdf

Version: 2024-02-01

		1040056	1474206	
9	857	9	9	
papers	citations	h-index	g-index	
9	9	9	1583	
all docs	docs citations	times ranked	citing authors	

#	Article	IF	CITATIONS
1	The interplay between cell signalling and the mevalonate pathway in cancer. Nature Reviews Cancer, 2016, 16, 718-731.	28.4	447
2	Susceptibility to simvastatin-induced toxicity is partly determined by mitochondrial respiration and phosphorylation state of Akt. Biochimica Et Biophysica Acta - Molecular Cell Research, 2011, 1813, 2079-2087.	4.1	67
3	Immediate Utility of Two Approved Agents to Target Both the Metabolic Mevalonate Pathway and Its Restorative Feedback Loop. Cancer Research, 2014, 74, 4772-4782.	0.9	64
4	An actionable sterol-regulated feedback loop modulates statin sensitivity in prostate cancer. Molecular Metabolism, 2019, 25, 119-130.	6.5	55
5	Identifying molecular features that distinguish fluvastatin-sensitive breast tumor cells. Breast Cancer Research and Treatment, 2014, 143, 301-312.	2.5	52
6	Genome-wide RNAi analysis reveals that simultaneous inhibition of specific mevalonate pathway genes potentiates tumor cell death. Oncotarget, 2015, 6, 26909-26921.	1.8	52
7	Statin-Induced Cancer Cell Death Can Be Mechanistically Uncoupled from Prenylation of RAS Family Proteins. Cancer Research, 2018, 78, 1347-1357.	0.9	49
8	Simvastatin induces mitochondrial dysfunction and increased atrogin-1 expression in H9c2 cardiomyocytes and mice in vivo. Archives of Toxicology, 2016, 90, 203-215.	4.2	40
9	A pilot window-of-opportunity study of preoperative fluvastatin in localized prostate cancer. Prostate Cancer and Prostatic Diseases, 2020, 23, 630-637.	3.9	31